Literature DB >> 12885103

Angiotensin-converting enzyme inhibitors and type 2 diabetic nephropathy: a meta-analysis.

Robert A Hamilton1, Michael P Kane, Jason Demers.   

Abstract

OBJECTIVE: To perform a meta-analysis on studies evaluating the effect of angiotensin-converting enzyme (ACE) inhibitors on diabetic nephropathy in patients with type 2 diabetes mellitus.
METHODS: A computerized literature search was conducted for articles of studies comparing ACE inhibitors with a control in patients with diabetes, in which measurement of albuminuria or proteinuria was an outcome. Each article was abstracted by two of the authors. Data from the articles were presented as geometric or arithmetic means. The data were summarized separately by using standard techniques for meta-analysis. MAIN
RESULTS: Statistically significant reductions in albuminuria were observed regardless of whether data were described with geometric or arithmetic means. Both were associated with significant heterogeneity. When studies reporting geometric means were stratified and analyzed, the heterogeneity was lost and statistically significant reductions in albuminuria were observed. The same procedure was repeated for studies reporting arithmetic means, but heterogeneity remained.
CONCLUSION: The ACE inhibitors produce statistically significant reductions in albuminuria associated with significant heterogeneity of effect. Stratification reduces the heterogeneity and supports treatment with ACE inhibitors to reduce the progression of nephropathy in patients with type 2 diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12885103     DOI: 10.1592/phco.23.7.909.32726

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  2 in total

1.  Early administration of enalapril and losartan to patients with type 1 diabetes.

Authors:  Robert C Stanton
Journal:  Curr Diab Rep       Date:  2009-12       Impact factor: 4.810

2.  Treatment of diabetic nephropathy with Tripterygium wilfordii Hook F extract: a prospective, randomized, controlled clinical trial.

Authors:  Yongchun Ge; Honglang Xie; Shijun Li; Bo Jin; Jinhua Hou; Haitao Zhang; Mingjun Shi; Zhihong Liu
Journal:  J Transl Med       Date:  2013-05-31       Impact factor: 5.531

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.